Genoway Stock

Genoway ROA

The Return on Assets (ROA) of Genoway (ALGEN.PA) as of Sep 6, 2026 is 2.05 %. In the previous year, Return on Assets (ROA) was 5.76 % — a change of -64.46% (lower).

ROA

2.05 %

YoY

-64.46%

Last updated:

In 2026, Genoway's return on assets (ROA) was 2.05 %, a -64.46% increase from the 5.76 % ROA in the previous year.

The Genoway ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2018
2.90 EUR
Jan 1, 2019
-5.41 EUR
Jan 1, 2020
-2.49 EUR
Jan 1, 2021
-0.99 EUR
Jan 1, 2022
2.36 EUR
Jan 1, 2023
4.92 EUR
Jan 1, 2024
5.76 EUR
Jan 1, 2025
2.05 EUR
The Genoway ROA history
YEARROAYoY
2.05 %-64.46%
5.76 %+16.96%
4.92 %+108.39%
2.36 %-337.97%
-0.99 %-60.18%
-2.49 %-53.93%
-5.41 %-286.37%
2.90 %-74.19%
11.25 %+126.05%
4.98 %+1,296.80%
0.36 %+39.08%
0.26 %
Access this data via the Eulerpool API

Genoway Stock analysis

What does Genoway do? Genoway SA is a biotechnology company based in Lyon, France. It was founded in 2002 by Pierre Cadinot. The company specializes in the production of genetically modified mice for disease research and the development of new therapies. The business model of Genoway is to provide customers with customized genetically modified mice. The company offers a wide range of services, from consulting during the design phase to the delivery of modified mice. The company also offers services in the field of cell culture and transgene expression. Genoway is divided into different divisions to meet specific customer needs. For example, there is the "Knockout Mice" division, which specializes in producing mice that lack a specific target gene. These mice are used to study the function of the missing gene in vivo. Another area of Genoway is the production of "humanized mouse models". These are mice in which human genes have been inserted to model specific human diseases or to test the efficacy of drugs. These humanized mice are an important part of drug research in the pharmaceutical industry. Genoway also offers services in the field of inducible expression. This involves triggering the expression of a target gene in vivo to study the effects of the protein. This technology is particularly useful in the research of diseases such as cancer, where certain genes are only active in specific cells. In addition to these specialized services, Genoway also offers a wide range of standard services, such as the creation of stable cell lines or transgene expression in various organs and tissues. Genoway is a leading company in the development of genetically modified models for the study of human diseases. The company works closely with its customers to develop customized solutions that meet the specific requirements of each project. With its divisions and services, it aims to support its customers in the development of new therapies and drugs. Genoway is one of the most popular companies on Eulerpool.

ROA Details

Understanding Genoway's Return on Assets (ROA)

Genoway's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Genoway's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Genoway's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Genoway’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Genoway stock

Return on Assets (ROA) of Genoway is 2.05 % in 2026.

Return on Assets (ROA) of Genoway changed from 5.76 % to 2.05 %, representing a -64.46% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Genoway since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Genoway with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

Profitability — Genoway

All Key Metrics — Genoway